Purpose: To estimate the radiobiological parameters of three popular NTCP models, which describe the dose-response relations of carotid blowout syndrome (CBOS) after stereotactic body radiotherapy (SBRT). To evaluate the goodness-of-fit and the correlation of those models with CBOS. Methods: The study included 61 patients with inoperable locally recurrent head and neck cancer treated with SBRT using CyberKnife (Accuray, Sunnyvale, CA) at the Department of Radiation Oncology, Hacettepe University, Ankara, Turkey between June 2007 and March 2011. The dosevolume histograms of the internal carotid were exported from the plans of all the patients. The follow-up results regarding the end point of carotid blowout syndrome were collected retrospectively. Initially, univariable analyses (Wilcoxon rank-sum or Chi-square tests) and a multivariate logistic regression analysis were performed between the outcome data and a list of clinical and treatment factors to identify significant correlations. Additionally, the Lyman-Kutcher-Burman (LKB), Relative Seriality (RS), and Logit NTCP models were used to fit the clinical data. The fitting of the different models was assessed through the area under the receiver operating characteristic curve (AUC), Akaike information criterion (AIC), and Odds Ratio methods. Results: The clinical/treatment factors that were found to have a significant or close to significant correlations with acute CBOS were Age at the time of CK (P-value = 0.03), Maximum carotid dose (P-value = 0.06), and CK prescription dose (P-value = 0.08). Using D max , physical DVH, and EQD 2 Gy -DVH as the dosimetric metrics in the NTCP models, the derived LKB model parameters were: (a) D 50 = 45.8 Gy, m = 0.24, n = n/a; (b) D 50 = 44.8 Gy, m = 0.28, n = 0.01; and (c) D 50 = 115.8 Gy, m = 0.45, n = 0.01, respectively. The AUC values for the dosimetric metrics were 0.70, 0.68, and 0.61, respectively. The differences in AIC between the different models were less than 2 and ranged within AE0.9.
INTRODUCTION
Patients with locally advanced head and neck cancer report a rate of local recurrence or persistent disease in the range of 3%-50%, even though in many cases a combination of treatment modalities is applied. [1] [2] [3] For a small fraction of the patients, surgery can be performed, which has been associated with a better prognosis. [4] [5] [6] However, even in this case additional local treatment is necessary because of the high rate of local recurrence. [4] [5] [6] [7] [8] Reirradiation has been reported to increase local control and overall survival at the cost of serious toxicity, both in severity and rates (10%-40%). [9] [10] [11] Stereotactic body radiotherapy (SBRT) using CyberKnife (CK) (Accuray, Sunnyvale, CA, USA), which is a relatively new image-guided stereotactic radiosurgery and body radiotherapy device, is considered an eligible technique for reirradiation of recurrent head and neck cancer because of its ability to deliver high doses of radiation to the tumor while sparing the adjacent organs at risk. Lesions located close to the critical structures can be treated more effectively with CyberKnife compared to linacs because of the reduction in the intrafractional margins and the more steep dose fall-off at the periphery of the lesion. In two recent publications, the results of SBRT in such a group of patients were reported. 12, 13 Although the local control rate in those patients treated with SBRT was higher than that with IMRT, the occurrence of carotid blowout syndrome (CBOS) was relatively high (17.3% vs 5%).
Carotid blowout syndrome is one of the most devastating complications associated with reirradiation for head and neck cancers. It refers to the rupture of the carotid artery. The reported neurologic morbidity and mortality rates associated with this complication are 40% and 60%, respectively. 14 CBOS has three subtypes: threatened, impending, and acute. Threatened blowout refers to a clinically exposed vessel or radiologic evidence of tumor invasion to the vascular structure. Impending form is characterized by spontaneously resolving recurrent epistaxis attacs. Acute carotid blowout syndrome is profuse, uncontrollable bleeding. 15 The reported incidence of acute CBOS after reirradiation for recurrent head and neck cancers ranges between 3% and 10% depending on radiotherapy schema, being highest in large fraction size treatments. 16 The purpose of this study is to analyze dose/volume/outcome data from a retrospective clinical trial in order to estimate the values of commonly used NTCP models and their ability to accurately represent the incidence of CBOS; and additionally, to identify dose thresholds that could ensure lower risks of acute CBOS when they are satisfied .
METHODS

2.A. Patient selection and dose prescription
From July 2007 to March 2011, 75 patients were treated with SBRT using CyberKnife (Accuray, Sunnyvale, CA, USA) at the Department of Radiation Oncology, Hacettepe University, Ankara, Turkey. Of those patients, 65 had available clinical and treatment data (including D max to internal carotid) and 61 had DVH data for internal carotid. All the patients had recurrent, unresectable, and previously irradiated head and neck cancer and informed consent was obtained before reirradiation. All local instances of recurrence were confirmed either radiologically or histopathologically. A head and neck thermoplastic mask was used for patient immobilization and both CT and magnetic resonance imaging (MRI) (slice thickness: 1 mm) scans were performed with the patients in the treatment position. The images from the two imaging modalities were registered before contouring. The delineation of internal carotid was not part of the standard clinical practice at the time of treatment. So, for the patients that this structure had not initially been drawn, it was delineated retrospectively.
In their primary treatment, the patients received a median prescribed dose of 61.0 Gy (range, 30.0-70.0 Gy), which was delivered in fractional doses of 1.8-2.0 Gy. For the SBRT, the median dose to PTV was 30 Gy (range, 24-35 Gy). One patient was treated with three fractions to a dose of 30 Gy, three patients were treated with four fractions to doses of 24 and 28 Gy, and one patient received six fractions to a dose 32 Gy. The rest were treated with five fractions to a median dose of 30 Gy. A representative plan is shown in Fig. 1 , where the isodose lines and internal carotid are shown. The median tumor volume was 53.6 cm 3 (range: 3.7-214.3 cm 3 ) . No patients received chemotherapy during the SBRT treatment. However, 25 (38%) patients received cisplatin-based chemotherapy combinations for treatment of recurrent tumor. The follow-up visits were planned every month for the first 3 months after SBRT. The fourth visit was planned on the sixth month post-RT and every 6 months thereafter. A summary of the basic treatment details of each patient are provided in the file Supplement_A_Clini-cal_Data.xls. In this file, information about the volume of the GTV, treatment site (nasopharynx, oral cavity etc.), prescription dose of the primary RT, time elapsed from the primary RT, number of CK fractions, CK prescription dose, proportion of carotid circumference receiving 30 Gy and local control, is provided. The dose-volume histogram (DVH) of internal carotid was calculated for each patient from their treatment plans. In the Supplementary files B and C, the numerical values of the DVHs of the patients with and without CBOS are provided. These DVHs were correlated with the patient outcome data of CBOS. Figure 2 illustrates the distribution of the DVHs of all the patients with the volume being expressed in absolute and normalized units.
2.B. Radiobiological models
The doses in the DVHs were converted to equivalent doses of 2 Gy per fraction (EDQ 2 Gy ) based on the linear quadratic model. 17, 18 CBOS is considered to be a late complication. For this reason, a a/b value of 3 Gy was used to account for the fractionation effects of the physical dose.
where D is the physical dose, d is the dose per fraction. A dose distribution can be reduced to a single dose value using the generalized Equivalent Uniform Dose (gEUD) concept as follows: 19, 20 
where V i is the fractional subvolume of the organ being irradiated with a given dose and V tot is the total volume of the organ. n is a parameter describing the volume dependence of the organ. gEUD 2 Gy is then used in the Lyman-KutcherBurman (LKB) and Logit models as follows: 21 NTCPðrÞ
where NTCP(r) indicates the probability of response due to a given three-dimensional dose distribution.
gEUD is conceptually equivalent to the effective dose (D eff ) with parameter a = 1/n. In this analysis, the value of the parameter t was calculated in three different ways: (a) using a gEUD without correcting for the fractionation effect; (b) using a gEUD with fractionation correction to 2 Gy per fraction; and (c) using the maximum dose without fractionation correction (in this case the model is often called probit although the sigmoidal function is practically the same). The Logit model is a logistic equation, which uses a sigmoidal dose-response curve, commonly used in biology and it is defined in the following way:
The Relative Seriality (RS) model applies a different approach to account for the volume dependence and it is mathematically expressed as follows: 23, 24 NTCPðrÞ ¼ ½1 À
where
ÞÁðecÀln ln 2Þ (7) where P(D i ) is the probability of response of an organ having the reference volume and being irradiated to dose D i . From the NTCP values the biologically effective uniform dose ( D) can be derived by the following formula:
The basic parameters of each model are: D 50 , which is the dose for a complication rate of 50%, the slope (gradient) of the dose-response curve (m for LKB, k for Logit, and c for RS), and the parameter that accounts for the volume dependence of the organ (n for LKB and Logit, s for RS). Regarding the parameters describing volume dependence, it should indicated that n ? 0 and s ? 1 indicate organs of serial behavior, which is associated with the maximum dose (D max ) to the organ.
2.C. Statistical methods used in model fitting and goodness-of-fit evaluation
To examine how relevant factors, (age, gender, treatment pattern, diagnosis, number of fractions, local control, GTV volume, days between CK and previous radiotherapy, prescription dose of the primary RT, CK prescription dose, Maximum carotid dose, maximum plan dose, circumference of carotid receiving at least 30 Gy) were associated with complication (CBOS), we conducted two statistical analyses: (a) univariable analyses using Wilcoxon rank-sum tests (for numerical variables) or Chi-square tests (for categorical variables) (Table I) ; and (b) an exploratory multivariate logistic regression with stepwise variable selection with entry P-value at 0.30, and stay P-value at 0.35 (Table II) . In these analyses, non-numerical factors had to be coded. Those codes are provided in the Appendix (see Table A1 ). The univariable analyses and logistic regression analysis were conducted using SAS 9.4 (SAS Institute Cary, NC, USA).
The values of the parameters of the NTCP models and their 95% confidence intervals were determined using the maximum likelihood method. In this process, the predictions of the NTCP models were fitted to the clinical follow-up results by changing the values of the model parameters until best estimates could be reached. 25, 26 The profile likelihood method was used to determine the confidence intervals of the model parameters. For the 95% confidence region, the allowable difference from the maximum ln L max ð x i Þ À ln L max ðx i Þ is 1/2 9 3.84 = 1.92, for one degree of freedom.
The goodness-of-fit of the different NTCP models was assessed through the area under the receiver operating characteristic curve (AUC), maximum of the log-likelihood function, and Akaike information criterion (AIC). 27 More specifically, the AUC of a receiver operating characteristic (ROC) curve was computed and compared to the level of 0.5 (equivalent to a random predictor). The Akaike information criterion was used to compare the fitting and complexity of the different models. Finally, the Odds Ratio (OR) is a method, which is used to identify the doses beyond which the risk of toxicity increases. 28 In our study, we applied this method to find the radiobiological dose (gEUD or D) that is associated with not only the largest but also statistically significant OR.
RESULTS
After examining a number of demographic and treatmentrelated parameters using the univariate Wilcoxon rank-sum test, the ones that were found to have a significant or close to significant correlations with acute CBOS were Age at the time of CK, CK prescription dose, and Maximum carotid dose (Table I) . Chemotherapy use did not correlate with the development of acute CBOS. Cisplatin-based combination chemotherapy was given to 36% of the patients with acute CBOS, and to 38% of the remaining group. There are a number of clinical factors that may have an impact on the manifestation of CBOS.
To examine how closely relevant factors, such as Age at the time of CK, gender, treatment pattern, treatment site, number of fractions, local control, GTV volume, days between previous RT and CK, dose of primary RT, CK dose, maximum dose to carotid (from CK), max dose of CK plan, circumference of carotid receiving 30 Gy, were simultaneously associated with CBOS, we additionally conducted exploratory logistic regression with stepwise variable selection with entry P-value at 0.30, and stay P-value at 0.35. The variable selection analyses showed significant or close to significant correlations of CBOS with Age at the time of CK and Maximum carotid dose (see Table II ). Consequently, the multivariate logistic regression response model contained those factors and based on this model younger Age at the time of CK and higher Maximum carotid dose were associated with higher probability of CBOS. The response function from the multivariate logistic regression analysis is the following: logðORÞ ¼ log NTCP CBOS =NTCP noÀCBOS ð Þ À3:4254 À 0:054 Ã Age þ 0:0013 Ã D max (9) where the terms "Age" and "D max " refer to Age at the time of CK and maximum dose to carotid, respectively.
The predictive power of the average dose (D mean ), maximum dose (D max ), and a range of dose-volume metrics (V D ) of the internal carotid were examined by calculating their AUC values. Table III and Fig. 3 show the results for the different metrics (except for D mean , whose AUC value was close to 0.5).
In a quantitative form, Table III presents a summary of the average D max values to the internal carotid for the patients with and without CBOS. Additionally, the average values of the dose-volume metric V 34 , which correlated best with the outcome data are also shown. It is clear that in all the cases, the patients with CBOS have higher values than those without the symptom. The AUC values of the dosimetric metrics D max and V 34 were 0.71 and 0.67, respectively. For those metrics, the OR values of the cutoff points V34 ≤8 cc were 6.5 (1.3-33.5) and 6.7 (1.3-35.1), respectively. Subsequently, the values of the parameters of the NTCP models were determined for CBOS based on D max , physical DVH (this mean that for the LKB model, gEUD was calculated using physical dose rather than EQD 2 Gy ) and EQD 2 Gy -DVH (Table IV) . The corresponding dose-response curves for the examined models and structures are shown in fig. 5 . Model parameter values were also derived using the absolute DVHs and the results were very similar to those obtained using the normalized DVHs. Regarding the correlation of the NTCP prediction against the actual follow-up data, the D max -based NTCP fitting shows a little higher AUC value (0.70), than the DVH-based (0.62-0.68) and the EQD 2 Gy -DVH-based (0.60-0.61) models. Although D max is included in the DVH, the fitting is different when D max is used against the complete DVH. That is because other doses in the high dose tail of the DVH also show high correlations with outcome affecting the overall fitting when the complete DVH is used in NTCP modeling. So, the results of the modeling using D max or DVH are similar but not exactly the same. Normally, the two fits should coincide in serial organs when the dose-volume metric (V x ) derived from the DVH fit corresponds to the volume used to determine D max (e.g., 0.1 cm 3 ). The variation in the AIC values was small between the different models (58.2-60.8) ( Table A2 ). As a rule of thumb, a difference of around 2 values between any model against the model with the lowest AIC value suggests substantial evidence that the models are equivalent. 27 The statistical analysis showed that the differences in the respective series of NTCP values between the different dosimetric metrics were not statistically significant. The same finding was observed regarding the differences between the three NTCP models for the same metric (see Table A4 , Appendix).
DISCUSSION
Based on the results of the Wilcoxon rank-sum test and multivariate regression analysis it appears that Age at the time of CK has a significant impact on the manifestation of CBOS. The time between previous RT and CK as well as the prescribed dose of the previous RT showed poor correlation with CBOS. In Tables I and II it is interesting to notice that CK prescription dose and Maximum carotid dose have similar Pvalues between 0.05 and 0.1, which show close to significant correlation with CBOS. It would be ideal if the composite dose distribution from the previous RT and CK could be calculated and used for the present statistical analysis. However, there was no access to the plans of the previous RT and to the majority of the CK plans at the time of data processing and analysis. Unfortunately for this reason, an analysis of the dose covering different proportions of the circumference of carotid, was not possible. This information was available for 51 patients for the dose of 30 Gy, which is a lower dose than that of 34 Gy, which appears to correlate better with the outcome data. The P-value in this case was low (0.12) but not statistically significant. So, the question of whether the irradiation of the whole circumference of carotid is significantly associated with a higher risk for CBOS still remains. Similarly, it is found that the treatment pattern (daily CK or every other day) does not appear to have a significant impact on the outcome.
The univariate Wilcoxon rank-sum test showed that compared to the patients without CBOS, patients with CBOS tended to be younger at the time of CK (P-value = 0.03), had higher Maximum carotid dose (P-value = 0.06), and higher CK prescription dose (P-value = 0.08). Similarly, the multivariate logistic regression response model contained Age at the time of CK and Maximum carotid dose. Based on this model, younger age and higher Maximum carotid dose were associated with higher probability of CBOS.
Although there is an abundance of model parameter values in the literature regarding toxicity post-RT, there is lack of such parameters for CBOS. We have outlined the dose-response relations of carotid blowout syndrome after SBRT through three popular NTCP models via the goodnessof-fit method, and verified that keeping the maximum dose (D max ) constraint of the internal carotid less than 34 Gy would significantly reduce the risk for carotid blowout. As indicated by the results of the goodness-of-fit, the three models studied fitted the clinical data with similar accuracy, especially for the metrics of D max and physical DVH. Not surprisingly, the LKB and logistic models (same volume dependence parameter) are almost identical as has been indicated by previous studies. 29 The difference between those two models and the RS model is that although they are based on similar statistical properties and assumptions they handle the volume effect differently (RS gives more emphasis to the higher doses of the distribution). This makes the dose-response curves of those models to be close in the region of 50% response, but makes them deviate from each other in the high and low response levels. More important is the fact that all the results point to maximum dose to the internal carotid as the most strongly correlated variable with CBOS (in the RS model, s values approaching one (s?1) and in the LKB model, n values approaching zero (n?0) emphasize D max ). In the literature, we could not identify any other study deriving parameters for NTCP models for CBOS. In this study, in order to validate the goodness-of-fit, we applied the estimated parameters on the dataset from which they were derived. However, this type of validation properly requires an independent cohort of patients. Here, the goodness-of-fit test was performed mainly to identify differences between the models regarding the quality of fit.
The length of the internal carotid delineated was not the same between the patients. This has an impact in the DVH when the volume is expressed in terms of normalized volume. In order to examine the impact of this factor on our results, the correlation of DVH with CBOS was performed twice (using DVHs where the volume was expressed as percentage of the total delineated volume or as absolute volume in units of cm 3 ). Both analyses resulted in very similar model parameter values. This happened because the dose that correlated best with CBOS was D max and not a given dose-volume metric.
Regarding the correction of the doses using the LQ model, this is triggered not only by the general fractionation scheme applied but also by the nonuniformity of the dose distribution within internal carotid. So, conceptually in order to make two dose distributions comparable and correlate them with a given treatment outcome, the dose in every voxel needs to be converted to a common fractional dose, irrespective of the general fractionation scheme prescribed to the plan. However, in the present dataset there is no diversity between the patients with different fractionation schemes, and any relevant conclusions about achieving a better fit using physical doses against fractionation corrected doses should be treated with caution.
It is difficult to distinguish between those models, given the size of the dataset and the fact that those models share similar mathematical properties. However, the reason for applying all three of them is not so much to identify which is the superior one but mainly to provide the community with parameter values to use in future treatment plan comparison studies since different research groups have specific preferences and experience with given models.
Our study has a number of limitations. Mainly, the size of our dataset presently prevents us from performing subsample test validation of our models. A future goal should be to collect the clinical data of another cohort of patients and use it for model validation.
It must be stated that all the existing NTCP models have inherent limitations. For example, the volume effect of the different organs is not determined based on the spatial distribution of the functional subunits of the organs but on the shape of the applied dose distribution in the organ. An additional important limitation of the modeling and the analysis in general are the lack of information concerning time between irradiations, chemotherapy, and prior dose distributions for the patients. The NTCP models that were used in this study did not account for those factors. Yazici et al. 13 presented a simple strategy to decrease fatal carotid blowout syndrome, with three factors: (a) constraining the carotid D max to ≤34 Gy; (b) limiting the circumference of carotid receiving 30 Gy; and (c) applying an every-other-day treatment pattern. Although this initial dose-response model only confirmed the first factor, we still emphasize the importance of including the other two factors as a combined overall clinical strategy.
Regardless of the AUC, V 34 does not look like a promising clinically usable variable (based on the logistic regression fit of V 34 and D max shown in Fig. A1 , V 34 = 0% has an1 0% complication probability, which may come from the fact that two of the complications DVHs in Fig. 2 do not go as high as 34 Gy). D max looks like a much more reasonable clinical variable and the NTCP models strongly favor the highest dose end of the DVH (n = 0.01).
Although the P-values corresponding to the simple strategies of reducing the circumference of carotid that is irradiated to a high dose and to treat the patient every other day were greater than 0.05, given the severity of the complications and the simplicity of those recommendations, they may still be advisable. It was shown that all the examined NTCP models (LKB, Logit, and Relative Seriality) could fit the individual patient-reported outcome data with very similar accuracy. The D max -based NTCP predictions of frequency correlated a little better with the outcome data than the rest of the metrics. The values of the model parameters for the CBOS could not be compared with previously published values, because of a lack of such studies in the literature. Further investigation with a larger patient cohort could verify the suitability of using the values of the NTCP model as an additional constraint in SBRT treatment plan optimization. For this purpose and following the new guidelines of the American Association of Physicists in Medicine (AAPM) 30 and the recommendation of QUANTEC, 31 the complete DVHs and outcome data have been included in an APPENDIX to facilitate the possibility of meta-analyses for the different types of symptoms. 
